Complement system activation in cardiac and skeletal muscle pathology: Friend or foe?

Advances in Experimental Medicine and Biology

Volumn 734, Issue , 2013, Pages 207-218

  Syriga, Maro ^a   Mavroidis, Manolis ^a  

^a BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3 RECEPTOR; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C4 RECEPTOR; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C9; COMPLEMENT FACTOR I; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOGLOBULIN G; INTERLEUKIN 6; PEXELIZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; CELL HYPOXIA; CELL SURVIVAL; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; CONFERENCE PAPER; CYTOKINE RESPONSE; DERMATOMYOSITIS; DYSFERLINOPATHY; FATTY ACID SYNTHESIS; GLUCOSE METABOLISM; HEART DISEASE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HEART PROTECTION; HEART STRESS; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INNATE IMMUNITY; MUSCLE REGENERATION; MYASTHENIA GRAVIS; MYOPATHY; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; TREATMENT OUTCOME; ADAPTATION; DYSFERLIN MYOPATHY; FATTY ACID METABOLISM; HEART; HEART INFARCTION; HEART INJURY; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; MYOSITIS; PROTEIN FUNCTION; SKELETAL MUSCLE; STRESS;

EID: 84934436947     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-4118-2_14     Document Type: Conference Paper

References (82)

1. Abbott JD, Huang Y et al (2004) Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not suf ficient to induce homing in the absence of injury. Circulation 110(21):3300-33055
2. Askari AT, Unzek S et al (2003) Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 362(9385):697-7033
3. Basta M, Dalakas MC (1994) High-dose intravenous immunoglobulin exerts its Beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 94(5): 1729-17355
4. Cenacchi G, Fanin M et al (2005) Ultrastructural changes in dysferlinopathy support defective membrane repair mechanism. J Clin Pathol 58(2):190-1955
5. Chamberlain-Banoub J, Neal JW et al (2006) Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats. Clin Exp Immunol 146(2):278-2866
6. Chen XL, Tummala PE et al (1998) Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ Res 83(9):952-9599
7. Choi YH, Kurtz A et al (2011) Mesenchymal stem cells for cardiac cell therapy. Hum Gene Ther 22(1):3-177
8. Collins RA, Grounds MD (2001) The role of tumor necrosis factor-alpha (TNF-alpha) in skeletal muscle regeneration. Studies in TNF-alpha(-/-) and TNF-alpha(-/-)/LT-alpha(-/-) mice. J Histochem Cytochem 49(8):989-10011
9. Corti S, Salani S et al (2001) Chemotactic factors enhance myogenic cell migration across an endothelial monolayer. Exp Cell Res 268(1):36-444
10. Crawford MH, Grover FL et al (1988) Complement and neutrophil activation in the pathogenesis of ischemic myocardial injury. Circulation 78(6):1449-14588
11. Dalakas MC (2010a) Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol 6(3):129-1377
12. Dalakas MC (2010b) Inflammatory muscle diseases: a critical review on pathogenesis and therapies. Curr Opin Pharmacol 10(3):346-3522
13. Diepenhorst GM, van Gulik TM et al (2009) Complement-mediated ischemia-reperfusion injury: lessons learned from animal and clinical studies. Ann Surg 249(6):889-8999
14. Emslie-Smith AM, Engel AG (1990) Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol 27(4):343-3566
15. Engler R (1987) Consequences of activation and adenosine-mediated inhibition of granulocytes during myocardial ischemia. Fed Proc 46(7):2407-24122
16. Eriksson U, Kurrer MO et al (2003) Interleukin-6-de ficient mice resist development of autoimmune myocarditis associated with impaired upregulation of complement C3. Circulation 107(2):320-3255
17. Faraj M, Cianflone K (2004) Differential regulation of fatty acid trapping in mouse adipose tissue and muscle by ASP. Am J Physiol Endocrinol Metab 287(1):E150-E1599
18. Frangogiannis NG (2008) The immune system and cardiac repair. Pharmacol Res 58(2):88-1111
19. Gallardo E, Rojas-Garcia R et al (2001) In flammation in dysferlin myopathy: immunohistochemical characterization of 13 patients. Neurology 57(11):2136-21388
20. Gasque P, Morgan BP et al (1996) Human skeletal myoblasts spontaneously activate allogeneic complement but are resistant to killing. J Immunol 156(9):3402-34111
21. Han R, Frett EM et al (2010) Genetic ablation of complement C3 attenuates muscle pathology in dysferlin-de ficient mice. J Clin Invest 120(12):4366-43744
22. He S, Atkinson C et al (2009) A complement-dependent balance between hepatic ischemia/reperfusion injury and liver regeneration in mice. J Clin Invest 119(8):2304-23166
23. Hill JH, Ward PA (1971) The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med 133(4):885-9000
24. Hirahashi J, Mekala D et al (2006) Mac-1 signaling via Src-family and Syk kinases results in elastase-dependent thrombohemorrhagic vasculopathy. Immunity 25(2):271-2833
25. Hori M, Nishida K (2009) Oxidative stress and left ventricular remodelling after myocardial infarction. Cardiovasc Res 81(3):457-4644
26. Jain A, Sharma MC et al (2011) Detection of the membrane attack complex as a diagnostic tool in dermatomyositis. Acta Neurol Scand 123(2):122-1299
27. Jennings RB, Murry CE et al (1990) Development of cell injury in sustained acute ischemia. Circulation 82(33) (Suppl):II2-II122
28. Jennings RB, Steenbergen C Jr et al (1995) Myocardial ischemia and reperfusion. Monogr Pathol 37:47-800
29. Jiang B, Liao R (2010) The paradoxical role of in flammation in cardiac repair and regeneration. J Cardiovasc Transl Res 3(4):410-4166
30. Kaya Z, Afanasyeva M et al (2001) Contribution of the innate immune system to autoimmune myocarditis: a role for complement. Nat Immunol 2(8):739-7455
31. Kilgore KS, Homeister JW et al (1994) Sulfhydryl compounds, captopril, and MPG inhibit complement-mediated myocardial injury. Am J Physiol 266(1 Pt 2):H28-H355
32. Kimura Y, Madhavan M et al (2003) Expression of complement 3 and complement 5 in newt limb and lens regeneration. J Immunol 170(5):2331-23399
33. Kissel JT, Mendell JR et al (1986) Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 314(6):329-3344
34. Law SK, Gagnon J et al (1987) The primary structure of the beta-subunit of the cell surface adhesion glycoproteins LFA-1, CR3 and p150,95 and its relationship to the fibronectin receptor. EMBO J 6(4):915-9199
35. Legoedec J, Gasque P et al (1995) Expression of the complement alternative pathway by human myoblasts in vitro: biosynthesis of C3, factor B, factor H and factor I. Eur J Immunol 25(12):3460-34666
36. Legoedec J, Gasque P et al (1997) Complement classical pathway expression by human skeletal myoblasts in vitro. Mol Immunol 34(10):735-7411
37. Leivo I, Engvall E (1986) C3d fragment of complement interacts with laminin and binds to basement membranes of glomerulus and trophoblast. J Cell Biol 103(3):1091-11000
38. Lennon VA, Seybold ME et al (1978) Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. J Exp Med 147(4):973-9833
39. Lennon NJ, Kho A et al (2003) Dysferlin interacts with annexins A1 and A2 and mediates sarcolemmal wound-healing. J Biol Chem 278(50):50466-504733
40. Li X, Moody MR et al (2000) Cardiac-specific overexpression of tumor necrosis factor-alpha causes oxidative stress and contractile dysfunction in mouse diaphragm. Circulation 102(14):1690-16966
41. Liu J, Aoki M et al (1998) Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet 20(1):31-366
42. Lloyd-Jones D, Adams R et al (2009) Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119(3):480-4866
43. Long KK, Pavlath GK et al (2011) Sca-1 in fluences the innate immune response during skeletal muscle regeneration. Am J Physiol Cell Physiol 300(2):C287-C2944
44. MacLaren R, Cui W et al (2008) Adipokines and the immune system: an adipocentric view. Adv Exp Med Biol 632:1-211
45. Markiewski MM, Mastellos D et al (2004) C3a and C3b activation products of the third component of complement (C3) are critical for normal liver recovery after toxic injury. J Immunol 173(2):747-7544
46. Markiewski MM, DeAngelis RA et al (2009) The regulation of liver cell survival by complement. J Immunol 182(9):5412-54188
47. Mavroidis M, Capetanaki Y (2002) Extensive induction of important mediators of fibrosis and dystrophic calci fication in desmin-de ficient cardiomyopathy. Am J Pathol 160(3):943-9522
48. Mevorach D, Mascarenhas JO et al (1998) Complement-dependent clearance of apoptotic cells by human macrophages. J Exp Med 188(12):2313-23200
49. Neely JR, Morgan HE (1974) Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle. Annu Rev Physiol 36:413-4599
50. Nguyen HX, Tidball JG (2003) Interactions between neutrophils and macrophages promote macrophage killing of rat muscle cells in vitro. J Physiol 547(Pt 1):125-1322
51. Nozaki M, Raisler BJ et al (2006) Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci USA 103(7):2328-23333
52. Oksjoki R, Kovanen PT et al (2007) Function and regulation of the complement system in cardiovascular diseases. Front Biosci 12:4696-47088
53. Oram JF, Bennetch SL et al (1973) Regulation of fatty acid utilization in isolated perfused rat hearts. J Biol Chem 248(15):5299-53099
54. Psarras S, Mavroidis M et al (2011) Regulation of adverse remodelling by osteopontin in a genetic heart failure model. Eur Heart J [Epub ahead of print]. doi:10.1093/eurheart/ehr1199
55. Qi H, Tuzun E et al (2008) C5a is not involved in experimental autoimmune myasthenia gravis pathogenesis. J Neuroimmunol 196(1-2):101-1066
56. Rajabi M, Kassiotis C et al (2007) Return to the fetal gene program protects the stressed heart: a strong hypothesis. Heart Fail Rev 12(3-4):331-3433
57. Ratajczak MZ, Reca R et al (2006) Modulation of the SDF-1-CXCR4 axis by the third complement component (C3) - implications for traf fi cking of CXCR4+ stem cells. Exp Hematol 34(8):986-9955
58. Rawat R, Cohen TV et al (2010) Inflammasome up-regulation and activation in dysferlin-de ficient skeletal muscle. Am J Pathol 176(6):2891-29000
59. Rezkalla SH, Kloner RA (2002) No-reflow phenomenon. Circulation 105(5):656-6622
60. Sahashi K, Engel AG et al (1980) Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis. J Neuropathol Exp Neurol 39(2):160-1722
61. Saraste A, Pulkki K et al (1997) Apoptosis in human acute myocardial infarction. Circulation 95(2):320-3233
62. Schulz R, Heusch G (2009) Tumor necrosis factor-alpha and its receptors 1 and 2: Yin and Yang in myocardial infarction? Circulation 119(10):1355-13577
63. Soltys J, Kusner LL et al (2009) Novel complement inhibitor limits severity of experimentally myasthenia gravis. Ann Neurol 65(1):67-755
64. Spitzer D, Unsinger J et al (2004) ScFv-mediated in vivo targeting of DAF to erythrocytes inhibits lysis by complement. Mol Immunol 40(13):911-9199
65. Spuler S, Engel AG (1998) Unexpected sarcolemmal complement membrane attack complex deposits on nonnecrotic muscle fi bers in muscular dystrophies. Neurology 50(1):41-466
66. Suzuki N, Aoki M et al (2005) Expression pro fi ling with progression of dystrophic change in dysferlin-de ficient mice (SJL). Neurosci Res 52(1):47-600
67. Tang Z, McGowan BS et al (2004) Gene expression pro fi ling during the transition to failure in TNF-alpha over-expressing mice demonstrates the development of autoimmune myocarditis. J Mol Cell Cardiol 36(4):515-5300
68. Tidball JG (2005) Inflammatory processes in muscle injury and repair. Am J Physiol Regul Integr Comp Physiol 288(2):R345-R3533
69. Tidball JG, Villalta SA (2010) Regulatory interactions between muscle and the immune system during muscle regeneration. Am J Physiol Regul Integr Comp Physiol 298(5):R1173-R11877
70. Tidball JG, Wehling-Henricks M (2007) Macrophages promote muscle membrane repair and muscle fi bre growth and regeneration during modi fied muscle loading in mice in vivo. J Physiol 578(Pt 1):327-3366
71. Tsonis PA, Del Rio-Tsonis K et al (1996) Can insights into urodele limb regeneration be achieved with cell cultures and retroviruses? Int J Dev Biol 40(4):813-8166
72. Tuzun E, Scott BG et al (2003) Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis. J Immunol 171(7):3847-38544
73. Tuzun E, Scott BG et al (2004) Circulating immune complexes augment severity of antibody-mediated myasthenia gravis in hypogammaglobulinemic RIIIS/J mice. J Immunol 172(9):5743-57522
74. Tuzun E, Li J et al (2007) Pros and cons of treating murine myasthenia gravis with anti-C1q antibody. J Neuroimmunol 182(1-2):167-1766
75. Vandervelde S, van Luyn MJ et al (2005) Signaling factors in stem cell-mediated repair of infarcted myocardium. J Mol Cell Cardiol 39(2):363-3766
76. Venkatachalam K, Venkatesan B et al (2009) WISP1, a pro-mitogenic, pro-survival factor, mediates tumor necrosis factor-alpha (TNF-alpha)-stimulated cardiac fi broblast proliferation but inhibits TNF-alpha-induced cardiomyocyte death. J Biol Chem 284(21):14414-144277
77. Villalta SA, Nguyen HX et al (2009) Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy. Hum Mol Genet 18(3):482-4966
78. Vincent A, Drachman DB (2002) Myasthenia gravis. Adv Neurol 88:159-1888
79. Wenzel K, Zabojszcza J et al (2005) Increased susceptibility to complement attack due to down-regulation of decayaccelerating factor/CD55 in dysferlin-de ficient muscular dystrophy. J Immunol 175(9):6219-62255
80. Yasojima K, Kilgore KS et al (1998) Complement gene expression by rabbit heart: upregulation by ischemia and reperfusion. Circ Res 82(11):1224-12300
81. Zhou Y, Gong B et al (2007) Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis. J Immunol 179(12):8562-85677
82. Zwaka TP, Manolov D et al (2002) Complement and dilated cardiomyopathy: a role of sublytic terminal complement complex-induced tumor necrosis factor-alpha synthesis in cardiac myocytes. Am J Pathol 161(2):449-4577